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Abstract The aim of this study was to explore the diagnostic
and prognostic value of serum human kallikrein-related pep-
tidases 11 (KLK11) level in non-small cell lung cancer
(NSCLC). Serum specimens from 138 patients with NSCLC
and 40 healthy controls were collected. The concentration of
KLK11 was measured by enzyme-linked immunosorbent as-
say (ELISA). The concentration of KLK11 in NSCLC was
significantly higher compared to that in the controls (P<0.01).
The serum KLK11 levels decreased with stage, presence of
lymph node, and distant metastases, regardless of histology,
age, and sex. With a cutoff point of 1.05 ng/ml, KLK11
showed a good diagnostic performance for NSCLC. Univar-
iate analysis revealed that NSCLC patients with serum high
KLK11 had a longer overall survival (OS) and progression-
free survival (PFS) than those with low KLK11 (HR of 0.36,
P=0.002; HR of 0.46, P=0.009). Cox multivariate analysis
indicated that KLK11 was an independent prognostic indica-
tor of PFS and OS (HR of 0.53, P=0.042; HR of 0.48, P=
0.037). Kaplan–Meier survival curves further confirmed that
patients with high KLK11 have longer PFS and OS (P=0.003
and P=0.018, respectively). In conclusion, the measurement
of KLK11 might be a useful diagnostic and prognostic test for
NSCLC patients.
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Introduction
Lung cancer is the leading cause of cancer-related death
worldwide, with more than 1.2 million deaths each year [1].
Non-small cell lung cancer (NSCLC) accounts for 80–85% of
total lung malignancies [2]. Although advances in noninva-
sive methods have improved our ability to detect lung cancer,
more than 75 % of lung cancer patients present an advanced
stage of disease [3], and they have little prospect of effective
and curative treatment, with 5-year survival rates of less than
15 % [4].
Tumor markers play a key role in patient manage-
ment for many malignancies. The potential uses of
serum tumor markers include aiding early diagnosis,
determining prognosis, prospectively predicting response
or resistance to specific therapies, and monitoring ther-
apy in patients with advanced disease. Kallikrein-related
peptidases 11 (KLK11) is a member of the human
kallikrein gene family, which localized on chromosome
19q13.4 [5]. Recent studies have reported that KLK11
has been expressed in many cancers, including prostate
cancer [6], ovarian cancer [7], gastric cancer [8], as well
as rectal carcinoma [9]. An immunofluorometric assay
study demonstrated that KLK11 expression in ovarian
cancer tissues is a marker of favorable prognosis, since
patients with KLK-positive tumors exhibit a longer
progression-free survival (PFS) and overall survival
(OS) [10]. Additionally, Sasaki et al. [11] reported that
lower KLK11 mRNA expression in lung cancer is an
indicator of poor prognosis in patients with lung cancer.
However, there seems to be a paucity of research con-
cerned with serum KLK11 expression in NSCLC. For
this reason, the goal of the present study was to inves-
tigate the baseline serum levels of KLK11 in patients
with NSCLC to determine its potential diagnostic and
prognostic roles.
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A total of 138 patients with NSCLC were examined at the
Nanjing Chest Hospital between January 2006 andMay 2008.
The cohort of patients included 80 (58.0 %) male and 58
(42.0%) female subjects, with a median age of 56 years (range
45–68 years). The clinical features of the patients are summa-
rized in Table 1. Follow-up lasted through December 2012,
with a median follow-up period of 22 months for living
patients (range 3–80 months). PFS was defined as the time
interval between the date of diagnosis and the date of disease
relapse. OS was defined as the time interval between the date
of diagnosis and the date of death.
The diagnosis of lung cancer was made using various
methods: sputum cytology, fine-needle aspiration or bron-
choscopy, as dictated by the patient’s presentation. Patholo-
gists interpreted the cytology or histology of tissue biopsy.
Lung cancer was staged using a widely used classification
system, and the staging procedure included a clinical exami-
nation; CT of the chest, abdomen, and brain; abdominal
ultrasonography; bone scanning; and positron emission
tomography.
The study protocol was approved by the ethics committee
of Nanjing Chest Hospital. All patients provided written in-
formed consent before enrollment.
Measurement of serum KLK11 levels
Serum samples from each individual were obtained at the time
of diagnosis, before any therapeutic measures were started
(surgery, chemotherapy, or radiation). Samples were centri-
fuged at 1,500×g for 10 min at −4 °C. The supernatant was
stored at −80 °C for assessment of the levels of KLK11. The
KLK11 concentration was determined by ELISA with the
commercial KLK11 ELISA Ready-SET-Go kit (eBioscience,
San Diego, CA). All samples were blinded to the technolo-
gists running the assays, and the code was broken to the
statisticians after the database was constructed.
Statistical analysis
Statistical software (SPSS for Windows, version 18) was used
for the analysis. Differences between independent groups
were examined by the Mann–Whitney U test. To determine
the diagnostic accuracy of KLK11, receiver operating charac-
teristic (ROC) curves were retrieved from logistic regression
analysis and the area under the curve (AUC) was calculated.
Univariate survival analysis was performed using the Kaplan–
Meier method and the log-rank test. Multivariate analysis was
conducted to determine an independent impact on survival
using the Cox proportional hazard method. P<0.05 was con-
sidered statistically significant.
Results
Comparison of serumKLK11 levels betweenNSCLC patients
and controls
As shown in Fig. 1, the concentration of KLK11 was signif-
icantly higher in patients with NSCLC (2.04±0.86 ng/ml)
than in those with the controls (0.93±0.52 ng/ml) (P<0.01).
Diagnostic value of KLK11 in NSCLC
A ROC curve analysis was carried out to assess the value of
KLK11 in NSCLC. The area under the ROC curve was 0.892
(confidence interval (95 % CI) 0.841–0.942). With a cutoff
point of 1.05 ng/ml, which was defined as the normal value
based on the mean value, plus two standard deviation obtained
from healthy controls, serum KLK11 has a sensitivity of
65.9 % (91/138), a specificity of 82.5 % (33/40), an accuracy
of 69.7% (124/178), a positive predictive value of 92.9% (91/
98), and a negative predictive value of 41.3 % (33/80) (Fig. 2).
Table 1 Clinical characteristics of NSCLC patients and controls
Variables NSCLC Control P value
Subject, no. 138 40
Age, year 57.8±10.2 54.6±7.8 0.614
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Fig. 1 Levels of KLK11 in NSCLC. Among 138 NSCLC patients, the
serum levels of KLK11 were 2.04±0.86 ng/ml, which were significantly
higher than 0.93±0.52 ng/ml in healthy controls (P<0.01)
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Relationship between serum KLK11 levels
and clinicopathologic factors
The relationships between KLK11 levels and clinicopatholog-
ic factors of lung cancer patients are shown in Table 2. The
serum KLK11 levels did not differ significantly with age (P=
0.569), sex (P=0.505), or histology (P=0.713). The levels of
KLK11 were significantly correlated with tumor-node-
metastasis (TNM) stage (P=0.000), lymph node metastases
(P=0.000), and distant metastases (P=0.000).
Association of serum KLK11 levels with survival
Finally, we determined whether the baseline serum concentra-
tion of KLK11 would be a prognostic marker in NSCLC. The
cutoff point of 1.05 ng/ml was selected to categorize patients
as KLK11-high or low. Univariate analysis showed that serum
KLK11 level was significantly correlated OS (P=0.002) and
PFS (P=0.009) (Table 3).
In multivariate analysis, high KLK11 was found to be
significantly associated with a longer PFS and OS (HR 0.53
and 0.48; P=0.042 and P=0.037, respectively). Kaplan–
Meier survival curves (Fig. 3) further demonstrate that lung
cancer patients with high KLK11 have substantially longer
PFS and OS (P<0.05), compared to those with low KLK11
cancer. As expected, disease stage was found to be strongly
associated with decreased PFS and OS, in both univariate and
multivariate analyses (P<0.05).
Discussion
During the last few years, numerous studies have been pub-
lished which attempt to refine our understanding of determi-
nants of prognosis in lung cancer by analyzing tumor-
associated markers thought to be of biologic relevance in the
carcinogenic process. Proteolytic enzymes of several catalytic
classes have emerged as important prognostic factors in can-
cer [12]. Among these enzymes are many members of human
tissue kallikrein family of secreted serine proteases, including
KLK11, a promising biomarker for lung cancer diagnosis, and
prognosis [11,13].
In the present study, serum KLK11 levels were significant-
ly elevated in patients with lung cancer compared with control
subjects, making them potential adjunctive tools for diagnosis
of lung cancer. Furthermore, at a cutoff point of 1.05 ng/ml,
KLK11 had a sensitivity of 91.3 % and a specificity of 72.5 %
for the prediction of lung cancer. Importantly, the serum
KLK11 levels did not differ significantly with age, gender,
and histology. The levels of KLK11 were significantly corre-
lated with TNM stage, the presence of lymph node, and distant
metastases.
Several previous studies have reported an association be-
tween kallikrein mRNA expression and cancer prognosis
[14–16]. KLK5 and KLK4 have been associated with poor
prognosis in ovarian cancer, and KLK5 has also been shown
to be associated with poor prognosis in breast cancer [17,18].
In contrast, KLK8 and KLK9 expression have been reported
to be favorable prognosis in ovarian cancer [19,20]. In addi-
tion, KLK12 is reported to be an independent and favorable
prognostic marker for breast cancer [21]. Sasaki et al. [11]
have indicated that there is a significant correlation between
decreased KLK11 mRNA expression level and poor progno-
sis in lung cancer. This study supports the increasing body of
Fig. 2 ROC of KLK11 for the diagnosis of NSCLC. Serum levels of
KLK11 among 138 NSCLC patients and 40 healthy controls were deter-
mined. The diagnostic potentials of KLK11 were assessed by ROC
curves. The AUC value was 0.892
Table 2 The clinicopathological factors of NSCLC and the association
with KLK11 levels
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literature demonstrating the expression of kallikrein family
gene involvement in the prognosis of human cancers. The
most striking association we observed in NSCLC patients
was a significant correlation between increased KLK11 level
and favorable prognosis. We have demonstrated that high
KLK11 was significantly associated with an increased PFS
and OS in univariate analysis. This relationship was further
illustrated in the Kaplan–Meier survival curves. Multivariate
analysis also indicated that KLK11 was an independent indi-
cator of PFS and OS.
Table 3 Univariate and multivariate analysis of KLK11 status with regard to PFS and OS
Variables PFS OS
HR 95 % CI P value HR 95 % CI P value
Univariate analysis
KLK11 (Low vs. High) 0.46 0.25–0.82 0.009 0.36 0.19–0.69 0.002
Age (≥60 vs. <60) 1.23 0.67–2.28 0.506 1.18 0.59–2.13 0.792
Gender (Male vs. Female) 1.32 0.71–1.82 0.782 1.19 0.69–1.98 0.673
Histology (AC vs. SCC) 1.83 0.59–2.13 0.792 1.34 0.65–1.98 0.546
Stage (I–II vs. III–IV) 1.33 0.65–2.21 0.001 0.93 1.09–3.44 0.025
Lymph node metastases (absent vs. present) 1.42 1.04–1.94 0.271 1.77 0.32–1.66 0.347
Distant metastases (absent vs. present) 1.98 1.03–3.01 0.039 1.87 1.04–2.99 0.075
Multivariate analysis
KLK11 (low vs. high) 0.53 0.29-0.97 0.042 0.48 0.24-0.95 0.037
Age (≥60 vs. <60) 0.98 0.52-1.94 0.834 1.06 1.28-3.01 0.128
Gender (male vs. Female) 1.28 0.67-1.89 0.672 1.14 0.46-2.14 0.542
Histology (AC vs. SCC) 1.37 1.04-2.33 0.315 1.26 0.64-2.56 0.424
Stage (I–II vs. III–IV) 1.25 0.56-2.26 0.001 1.96 1.02-3.77 0.043
Lymph node metastases (absent vs. present) 1.13 0.81-1.57 0.148 1.84 0.33-1.72 0.334
Distant metastases (absent vs. present) 1.44 0.85-1.97 0.098 1.89 0.99-2.35 0.051
HR hazard ratio, CI confidence interval
Fig. 3 Kaplan–Meier survival
curves for PFS and OS in patients
with KLK11-high and -low
NSCLC. Log-rank test
determined that the PFS and OS
in high KLK11 group were
significantly longer than those in
the low KLK11 group (P=0.003;
P=0.018)
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In conclusion, our data suggest that serum KLK11 may be
a useful diagnostic biomarker and shows a promising potential
as prognostic marker in NSCLC patients. More large-scale
prospective studies are warranted to confirm the findings.
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